Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$22.61
-3.5%		$21.55
$10.01
▼
$42.12
$65.78M1.538,530 shs6,726 shs
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$1.89
$2.80
$1.71
▼
$16.00
$49.67M1.29355,991 shs689,737 shs
HIND
Vyome
$2.10
$2.15
$1.75
▼
$6.63
$14.74M1.516,142 shs194,507 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.89
$5.47
$3.94
▼
$9.10
$55.50M0.718,072 shs77,052 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%-2.77%-7.09%-0.99%+22.63%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
0.00%-7.80%-37.83%-54.35%-83.30%
HIND
Vyome
0.00%+1.94%-6.67%-3.23%+209,999,900.00%
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%-3.74%-11.25%-18.36%-40.73%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollomics Inc. stock logo
APLM
Apollomics
$22.61
-3.5%		$21.55
$10.01
▼
$42.12
$65.78M1.538,530 shs6,726 shs
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
$1.89
$2.80
$1.71
▼
$16.00
$49.67M1.29355,991 shs689,737 shs
HIND
Vyome
$2.10
$2.15
$1.75
▼
$6.63
$14.74M1.516,142 shs194,507 shs
ImageneBio, Inc. stock logo
IMA
ImageneBio
$4.89
$5.47
$3.94
▼
$9.10
$55.50M0.718,072 shs77,052 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollomics Inc. stock logo
APLM
Apollomics
0.00%-2.77%-7.09%-0.99%+22.63%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
0.00%-7.80%-37.83%-54.35%-83.30%
HIND
Vyome
0.00%+1.94%-6.67%-3.23%+209,999,900.00%
ImageneBio, Inc. stock logo
IMA
ImageneBio
0.00%-3.74%-11.25%-18.36%-40.73%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollomics Inc. stock logo
APLM
Apollomics
1.00
SellN/AN/A
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
2.50
Moderate Buy$19.75944.97% Upside
HIND
Vyome
2.50
Moderate Buy$9.25340.48% Upside
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.20
Hold$29.00493.05% Upside

Current Analyst Ratings Breakdown

Latest HIND, IMA, APLM, and ELTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/3/2026
HIND
Vyome
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$3.50
9/1/2026
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/21/2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$28.00
8/18/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/28/2026
Apollomics Inc. stock logo
APLM
Apollomics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollomics Inc. stock logo
APLM
Apollomics
$8.50M7.74N/AN/A($2.89) per share-7.82
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/A$0.09 per shareN/A
HIND
Vyome
$320K46.07N/AN/A$0.67 per share3.13
ImageneBio, Inc. stock logo
IMA
ImageneBio
$800K69.38N/AN/A$11.91 per share0.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollomics Inc. stock logo
APLM
Apollomics
-$10.94MN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$39.57M-$2.17N/AN/AN/AN/A-1,266.43%-139.94%11/12/2026 (Estimated)
HIND
Vyome
-$10.26M-$3.37N/AN/AN/A-3,024.84%-197.33%-138.14%N/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$45.35M-$4.58N/AN/AN/AN/A-38.99%-34.84%N/A

Latest HIND, IMA, APLM, and ELTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
-$0.5375-$0.43+$0.1075-$0.43N/AN/A
8/12/2026Q2 2026
HIND
Vyome
N/A-$0.10N/A-$0.10N/A$0.27 million
8/5/2026Q2 2026
ImageneBio, Inc. stock logo
IMA
ImageneBio
-$0.90-$0.63+$0.27-$0.63N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apollomics Inc. stock logo
APLM
Apollomics
N/AN/AN/AN/AN/A
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollomics Inc. stock logo
APLM
Apollomics
N/A
0.96
0.96
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
1.20
2.77
2.77
HIND
Vyome
N/A
4.37
4.37
ImageneBio, Inc. stock logo
IMA
ImageneBio
N/A
21.47
21.47

Institutional Ownership

CompanyInstitutional Ownership
Apollomics Inc. stock logo
APLM
Apollomics
19.13%
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
35.03%
HIND
Vyome
22.06%
ImageneBio, Inc. stock logo
IMA
ImageneBio
75.00%

Insider Ownership

CompanyInsider Ownership
Apollomics Inc. stock logo
APLM
Apollomics
N/A
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
28.65%
HIND
Vyome
33.00%
ImageneBio, Inc. stock logo
IMA
ImageneBio
2.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollomics Inc. stock logo
APLM
Apollomics
152.91 millionN/ANot Optionable
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
N/A26.28 million18.75 millionNot Optionable
HIND
Vyome
187.02 million4.70 millionN/A
ImageneBio, Inc. stock logo
IMA
ImageneBio
1811.35 million11.10 millionNot Optionable

Recent News About These Companies

ImageneBio, Inc. (NASDAQ:IMA) Receives $29.00 Average PT from Analysts
September 20 at 1:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31033813
ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-imagenebio-inc-nasdaq-ima-receives-consensus-rating-of-hold-from-brokerages-2026-09-15/
ImageneBio Corporate Event Calendar | NASDAQ:IMA
September 13, 2026  |  benzinga.comhttps://www.benzinga.com/quote/IMA/events
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york-1036530172
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358135/0/en/imagenebio-to-participate-in-h-c-wainwright-28th-annual-global-investment-conference-in-new-york.html
ImageneBio, Inc. (NASDAQ:IMA) Sees Significant Decline in Short Interest
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-imagenebio-inc-nasdaq-ima-sees-significant-decline-in-short-interest-2026-08-26/
Trails Edge Capital Partners LP Invests $1.66 Billion in ImageneBio, Inc. $IMA
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-trails-edge-capital-partners-lp-invests-166-billion-in-imagenebio-inc-ima-2026-08-26/
Cable Car Capital LP Makes New Investment in ImageneBio, Inc. $IMA
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-cable-car-capital-lp-makes-new-investment-in-imagenebio-inc-ima-2026-08-26/
What is HC Wainwright's Estimate for ImageneBio Q3 Earnings?
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-imagenebio-q3-earnings-2026-08-25/
ImageneBio (NASDAQ:IMA) Stock Rating Upgraded by HC Wainwright
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/imagenebio-nasdaqima-stock-rating-upgraded-by-hc-wainwright-2026-08-22/
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1036468494
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346489/0/en/imagenebio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
ImageneBio, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026
August 6, 2026  |  zonebourse.comZ
ImageneBio Reports Second Quarter 2026 Financial Results
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339263/0/en/imagenebio-reports-second-quarter-2026-financial-results.html
ImageneBio Strengthens Leadership with New CFO Appointment
July 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/imagenebio-strengthens-leadership-with-new-cfo-appointment?utm_source=marketbeat.com&utm_medium=referral
ImageneBio Stock Short Interest Report | NASDAQ:IMA | Benzinga
July 7, 2026  |  benzinga.comhttps://www.benzinga.com/quote/IMA/short-interest
ImageneBio Appoints Matt Robbins as General Counsel
July 7, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/imagenebio-appoints-matt-robbins-as-general-counsel-1036302734
ImageneBio Appoints Matt Robbins as General Counsel
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323019/0/en/imagenebio-appoints-matt-robbins-as-general-counsel.html
ImageneBio, Inc. Common Stock
June 27, 2026  |  fxempire.comF
ImageneBio, Inc. Common Stock (IMA) SEC Filings
June 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ima/sec-filings
ImageneBio Shareholders Back Directors and Governance Proposals
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/imagenebio-shareholders-back-directors-and-governance-proposals?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Broadcom logo displayed on a computer chip embedded in a circuit board with glowing blue connections.
The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
By Leo Miller | September 3, 2026
Adobe logo displayed on a wall behind an office desk with a laptop, notebook, and pens.
Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
By Dan Schmidt | September 14, 2026
J.M. Smucker logo card on a table with jam, peanut butter, coffee, strawberries, and toast.
J.M. Smucker Stock's Rally Has More Than Tariffs Behind It
By Chris Markoch | September 2, 2026
A Zoox autonomous vehicle drives on a city street in front of an Amazon office building with logo.
Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
By Sam Quirke | August 29, 2026
Dutch Bros drive-thru location with windmill logo signage and cars in line at dusk.
Dutch Bros Sell-Off Creates a Growth Opportunity
By Peter Frank | September 1, 2026
Apollomics stock logo

Apollomics NASDAQ:APLM

$22.60 -0.82 (-3.48%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$22.60 0.00 (0.00%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Elicio Therapeutics stock logo

Elicio Therapeutics NASDAQ:ELTX

$1.89 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$1.91 +0.02 (+1.06%)
As of 09/18/2026 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Vyome NASDAQ:HIND

$2.10 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.01 -0.09 (-4.10%)
As of 09/18/2026 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

ImageneBio stock logo

ImageneBio NASDAQ:IMA

$4.89 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$4.82 -0.07 (-1.53%)
As of 09/18/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas